Background
Methods
Study population and definition
Perioperative management and follow-up protocol
Outcomes and data collection
Allocation system for lung transplantation in South Korea
Statistical analysis
Results
Characteristics of the study population and comparison of characteristics of patients with IPF and non-IPF ILD
Characteristic | Total | IPF | Non-IPF ILD | P-value | |
---|---|---|---|---|---|
Pre-existing acute exacerbation* | 52 (48.1) | 37 (52.9) | 15 (39.5) | 0.184 | |
Number of recipients | 108 | 70 | 38 | ||
Mean recipient age, years | 57.5 ± 8.2 | 59.8 ± 6.4 | 53.3 ± 9.5 | < 0.001 | |
Male sex | 77 (71.3) | 57 (81.4) | 20 (52.6) | 0.002 | |
BMI, kg/m2 | 22.4 ± 3.7 | 22.5 ± 3.3 | 22.2 ± 4.3 | 0.712 | |
Diabetes mellitus | 23 (21.3) | 14 (20.0) | 9 (23.7) | 0.665 | |
Ever smoker | 61 (56.5) | 46 (65.7) | 15 (39.5) | 0.009 | |
FVC, % predicted | 44.1 ± 14.5 | 44.5 ± 14.2 | 43.4 ± 15.3 | 0.750 | |
DLco, % predicted | 24.3 ± 12.6 | 23.7 ± 11.8 | 25.5 ± 14.3 | 0.554 | |
ILD-GAP index | 4.2 ± 1.7 | 5.1 ± 1.2 | 2.3 ± 0.9 | < 0.001 | |
Pre-existing pulmonary hypertension | 49 (45.4) | 31 (44.3) | 18 (47.4) | 0.759 | |
Preoperative infection | 29 (26.9) | 18 (25.7) | 11 (28.9) | 0.717 | |
Prior thoracic surgery | 46 (42.6) | 33 (47.1) | 13 (34.2) | 0.194 | |
Pirfenidone use | 37 (34.3) | 36 (51.4) | 1 (2.6) | < 0.001 | |
Nintedanib use | 7 (6.5) | 7 (10.0) | 0 (0.0) | 0.050 | |
Preoperative steroid use | 93 (85.2) | 57 (81.4) | 36 (94.7) | 0.189 | |
<0.5 mg/kg/day | 65 (60.2) | 42 (60.0) | 23 (60.5) | ||
0.5–1.0 mg/kg/day | 18 (16.7) | 10 (14.3) | 8 (21.1) | ||
>1.0 mg/kg/day | 10 (9.3) | 5 (7.1) | 5 (13.2) | ||
Preoperative MV | 81 (75.0) | 50 (71.4) | 31 (81.6) | 0.245 | |
Duration of preoperative MV (days) | 15.3 ± 18.5 | 14.3 ± 19.2 | 17.1 ± 17.1 | 0.473 | |
Preoperative ECMO | 69 (63.9) | 41 (58.6) | 28 (73.7) | 0.118 | |
Duration of preoperative ECMO (days) | 14.6 ± 12.4 | 13.2 ± 11.3 | 16.6 ± 13.8 | 0.270 | |
Ischemic time (min) | 334.2 ± 77.6 | 330.6 ± 76.5 | 340.8 ± 80.1 | 0.518 | |
Postoperative ECMO | 7 (6.5) | 3 (4.3) | 4 (10.5) | 0.239 | |
Length of postoperative ICU stay (days) | 34.1 ± 106.6 | 24.5 ± 27.9 | 51.8 ± 175.8 | 0.348 |
Comparison of characteristics of patients with and without pre-existing acute exacerbation
Characteristic | Total | Acute exacerbation | No acute exacerbation | P-value |
---|---|---|---|---|
Number of recipients | 108 | 52 | 56 | |
Mean recipient age, years | 57.5 ± 8.2 | 58.2 ± 7.7 | 56.8 ± 8.6 | 0.393 |
Male sex | 77 (71.3) | 37 (71.2) | 40 (71.4) | 0.975 |
BMI, kg/m2 | 22.4 ± 3.7 | 22.3 ± 3.9 | 22.5 ± 3.5 | 0.813 |
Diagnosis | 0.184 | |||
IPF | 70 (64.8) | 37 (71.2) | 33 (58.9) | |
Non-IPF ILD | 38 (35.2) | 15 (28.8) | 23 (41.1) | |
CTD-ILD/IPAF | 19 (17.6) | 6 (11.5) | 13 (23.2) | |
SSc-ILD | 4 (3.7) | 1 (1.9) | 3 (5.4) | |
SJS-ILD | 4 (3.7) | 2 (3.8) | 2 (3.6) | |
IIM-ILD | 5 (4.6) | 1 (1.9) | 4 (7.1) | |
Other CTD-ILD/IPAF | 6 (5.6) | 2 (3.8) | 4 (7.1) | |
Idiopathic NSIP | 6 (5.6) | 5 (9.6) | 1 (1.8) | |
Chronic HP | 2 (1.9) | 0 | 2 (3.6) | |
Unclassifiable ILD | 11 (6.5) | 7 (13.5) | 7 (12.5) | |
Diabetes mellitus | 23 (21.3) | 7 (13.5) | 16 (28.6) | 0.055 |
Ever smoker | 61 (56.5) | 33 (63.5) | 28 (50.0) | 0.159 |
FVC, % predicted | 44.1 ± 14.5 | 44.1 ± 16.4 | 44.1 ± 12.9 | 0.987 |
DLco, % predicted | 24.3 ± 12.6 | 26.1 ± 12.1 | 22.7 ± 12.9 | 0.227 |
ILD-GAP index | 4.2 ± 1.7 | 4.4 ± 1.9 | 4.0 ± 1.6 | 0.280 |
Pre-existing pulmonary hypertension | 49 (45.4) | 23 (44.2) | 26 (46.4) | 0.819 |
Preoperative infection | 29 (26.9) | 17 (32.7) | 12 (21.4) | 0.187 |
Prior thoracic surgery | 46 (42.6) | 21 (40.4) | 25 (44.6) | 0.655 |
Pirfenidone use | 37 (34.3) | 19 (36.5) | 18 (32.1) | 0.631 |
Nintedanib use | 7 (6.5) | 4 (7.7) | 3 (5.4) | 0.709 |
Preoperative steroid use | 93 (86.1) | 47 (90.4) | 46 (82.1) | 0.216 |
<0.5 mg/kg/day | 65 (60.2) | 32 (61.5) | 33 (58.9) | |
0.5–1.0 mg/kg/day | 18 (16.7) | 9 (17.3) | 9 (16.1) | |
>1.0 mg/kg/day | 10 (9.3) | 6 (11.5) | 4 (7.1) | |
Preoperative MV | 81 (75.0) | 50 (96.2) | 31 (55.4) | < 0.001 |
Duration of preoperative MV (days) | 15.3 ± 18.5 | 16.6 ± 12.3 | 13.9 ± 23.8 | 0.488 |
Preoperative ECMO | 69 (63.9) | 44 (84.6) | 25 (44.6) | < 0.001 |
Duration of preoperative ECMO (days) | 14.6 ± 12.4 | 14.6 ± 12.4 | 14.6 ± 12.7 | 0.998 |
Ischemic time (min) | 334.2 ± 77.6 | 331.7 ± 81.0 | 336.5 ± 74.9 | 0.750 |
Postoperative ECMO | 7 (6.5) | 5 (9.6) | 2 (3.6) | 0.258 |
Length of postoperative ICU stay (days) | 34.1 ± 106.6 | 28.0 ± 29.4 | 39.8 ± 145.7 | 0.569 |
Mean follow-up (years) | 3.2 ± 2.6 | 3.0 ± 2.7 | 3.3 ± 2.6 | 0.439 |
90-day survival, % | 89.9 | 86.5 | 92.9 | |
1-year survival, % | 78.7 | 73.1 | 83.9 | |
3-year survival, % | 70.1 | 60.1 | 79.6 |
Effect of pre-existing acute exacerbation on survival after lung transplantation
Characteristic | Total | Patients who survived | Patients who did not survive | P-value |
---|---|---|---|---|
Number of recipients | 108 | 72 | 36 | |
Mean recipient age, years | 57.5 ± 8.2 | 56.7 ± 8.4 | 59.0 ± 7.7 | 0.169 |
Male sex | 77 (71.3) | 50 (69.4) | 27 (75.0) | 0.547 |
BMI, kg/m2 | 22.4 ± 3.7 | 22.2 ± 3.4 | 22.9 ± 4.1 | 0.336 |
Diagnosis | 0.254 | |||
IPF | 70 (64.8) | 44 (61.1) | 26 (72.2) | |
Non-IPF ILD | 38 (35.2) | 28 (38.9) | 10 (27.8) | |
CTD-ILD/IPAF | 19 (17.6) | 10 (13.9) | 9 (25.0) | |
SSc-ILD | 4 (3.7) | 4 (5.6) | 0 | |
SJS-ILD | 4 (3.7) | 2 (2.8) | 2 (5.6) | |
IIM-ILD | 5 (4.6) | 2 (2.8) | 3 (8.3) | |
Other CTD-ILD/IPAF | 6 (5.6) | 2 (2.8) | 4 (11.1) | |
Idiopathic NSIP | 6 (5.6) | 6 (8.3) | 0 (0.0) | |
Chronic HP | 2 (1.9) | 2 (2.8) | 0 | |
Unclassifiable ILD | 11 (6.5) | 10 (13.9) | 1 (2.8) | |
Diabetes mellitus | 23 (21.3) | 15 (20.8) | 8 (22.2) | 0.868 |
Ever smoker | 61 (56.5) | 40 (55.6) | 21 (58.3) | 0.784 |
FVC, % predicted | 44.1 ± 14.5 | 42.9 ± 12.1 | 44.8 ± 15.7 | 0.570 |
DLco, % predicted | 24.3 ± 12.6 | 24.3 ± 12.2 | 24.3 ± 12.9 | 0.999 |
ILD-GAP index | 4.2 ± 1.7 | 4.4 ± 2.0 | 4.1 ± 1.6 | 0.487 |
Pre-existing pulmonary hypertension | 49 (45.4) | 30 (41.7) | 19 (52.8) | 0.274 |
Preoperative infection | 29 (26.9) | 19 (26.4) | 10 (27.8) | 0.878 |
Pre-existing acute exacerbation | 52 (48.1) | 29 (40.3) | 23 (63.9) | 0.021 |
Prior thoracic surgery | 46 (42.6) | 30 (41.7) | 16 (44.4) | 0.783 |
Pirfenidone use | 37 (34.3) | 26 (36.1) | 11 (30.6) | 0.566 |
Nintedanib use | 7 (6.5) | 3 (4.2) | 4 (11.1) | 0.219 |
Preoperative steroid use | 93 (86.1) | 59 (81.9) | 34 (94.4) | 0.077 |
<0.5 mg/kg/day | 65 (60.2) | 41 (56.9) | 24 (66.7) | |
0.5–1.0 mg/kg/day | 18 (16.7) | 11 (15.3) | 7 (19.4) | |
>1.0 mg/kg/day | 10 (9.3) | 7 (9.7) | 3 (8.3) | |
Preoperative MV | 81 (75.0) | 53 (73.6) | 28 (77.8) | 0.637 |
Duration of preoperative MV (days) | 15.3 ± 18.5 | 14.7 ± 19.1 | 16.6 ± 17.4 | 0.635 |
Preoperative ECMO | 69 (63.9) | 46 (63.9) | 23 (63.9) | > 0.999 |
Duration of preoperative ECMO (days) | 14.6 ± 12.4 | 13.5 ± 11.2 | 16.8 ± 14.6 | 0.297 |
Ischemic time (min) | 334.2 ± 77.6 | 335.8 ± 81.3 | 330.9 ± 70.3 | 0.763 |
Postoperative ECMO | 7 (6.5) | 6 (8.3) | 1 (2.8) | 0.420 |
Length of postoperative ICU stay (days) | 34.1 ± 106.6 | 21.8 ± 19.3 | 58.8 ± 181.7 | 0.230 |
Mean follow-up (years) | 3.2 ± 2.6 | 4.1 ± 2.5 | 1.3 ± 2.0 | < 0.001 |
Factors influencing mortality in the study population
Parameter | Hazard ratio | 95% confidence interval | P-value |
---|---|---|---|
Univariable analysis | |||
Recipient age, years | 1.036 | 0.988–1.087 | 0.148 |
Male sex | 1.119 | 0.524–2.391 | 0.771 |
BMI, kg/m2 | 1.037 | 0.946–1.136 | 0.440 |
Diabetes mellitus | 0.988 | 0.450–2.170 | 0.976 |
Ever smoker | 0.999 | 0.511–1.953 | 0.997 |
FVC, % predicted | 0.991 | 0.965–1.018 | 0.500 |
DLco, % predicted | 1.003 | 0.973–1.033 | 0.870 |
ILD-GAP index | 1.067 | 0.855–1.332 | 0.567 |
Pre-existing pulmonary hypertension | 1.281 | 0.660–2.487 | 0.464 |
Preoperative infection | 0.990 | 0.476–2.060 | 0.979 |
IPF versus non-IPF ILD | 1.277 | 0.612–2.662 | 0.515 |
Pre-existing acute exacerbation | 2.072 | 1.048–4.097 | 0.036 |
Pirfenidone use | 0.925 | 0.453–1.891 | 0.831 |
Nintedanib use | 1.814 | 0.640–5.145 | 0.263 |
Preoperative steroid use | 3.610 | 0.864–15.086 | 0.078 |
Preoperative immunosuppressant use | 1.659 | 0.722–3.815 | 0.233 |
Preoperative MV | 1.191 | 0.541–2.624 | 0.664 |
Duration of preoperative MV (days) | 1.005 | 0.990–1.020 | 0.532 |
Preoperative ECMO | 1.117 | 0.563–2.215 | 0.751 |
Duration of preoperative ECMO (days) | 1.017 | 0.986–1.049 | 0.281 |
Postoperative ECMO | 0.442 | 0.060–3.237 | 0.422 |
Length of postoperative ICU stay (days) | 1.001 | 0.999–1.003 | 0.187 |
Prior thoracic surgery | 1.137 | 0.589–2.196 | 0.702 |
Multivariable analysis | |||
Recipient age, years | 1.048 | 0.995–1.104 | 0.078 |
Pre-existing acute exacerbation | 2.078 | 1.031–4.188 | 0.041 |
Preoperative steroid use | 3.976 | 0.925–17.085 | 0.064 |
Length of postoperative ICU stay (days) | 1.001 | 1.000–1.003 | 0.124 |